openPR Logo
Press release

GervanoRA Added Multiple Sclerosis: Pipeline Analysis- 2018to its Report Store

07-30-2018 09:35 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: GervanoRA Data Services

GervanoRA Added Multiple Sclerosis: Pipeline Analysis- 2018to

GervanoRA Data Services has released its latest pipeline analysis report, “Multiple Sclerosis (MS): Pipeline Analysis- 2018”. The report includes complete analysis of the pipeline molecules under development used for the treatment of MS. Report helps emerging companies to understand the strong competitor strategies through its key company profiles and SWOT analysis. Elaborated report information assist clients in understanding the current scenarios in drug development and help in development and design pipeline based in-licensing and out-licensing strategies. The Universities and Institutes added to the report are expected to play a vital role in the market growth. Apart from this, the discontinued and dormant projects poise clarity for the clients.
Required free sample report (PDF)?

https://www.gervanora.com/request-for-sample-report/

Multiple Sclerosis Overview
Multiple Sclerosis (MS) is a demyelinating disease of the nerve cell which disables brain and spinal cord (central nervous system). The body’s immune system attacks myelin sheath, the protective covering of the nerves causes the demyelination and leads to nerve damage. This damage slows down or blocks messages between CNS and body.
Report Highlights,
• GervanoRA’ analysis on Global MS epidemiology expects the population to be 3.46 million in 2023, increasing at a CAGR of 5%.
• MS therapy area has witnessed 31 major deals since 2010. Among 31, there are 11 acquisitions, 13 Collaboration agreements, five licensing agreements, and agreement termination, merger and settlement each one.
• Patent Analysis for the approved drugs for MS,
 Gilenya is protected with two US patents, two Europe patents, and three Japan patents
 Tecfidera protected with seven United States granted patents, out of which five patents term expiry is in 2018 and two patent’s expiry is in 2019. It is also protected with 2 EU patents
 Plegridy is protected by four United States patents with term expiry ranging from 2022 to 2026 and two Europe patents with term expiry of 2019 and 2023
 Ampyra/Fampyra (European Union Trade name) is protected with six issued United States patents and two Europe patents
 Lemtrada’s patents covering intellectual rights on compound has expired in United States, European Union and Japan
• As per the GervanoRA MS drug pipeline database, we have 74 company pipeline molecules and 51 molecules of universities and institutes.
• Based on GervanoRA’s estimation, around five molecules are expected to get regulatory approvals in 2019.
• Based on our analytics, we have segmented the trials which are terminated and withdrawn by company for various reasons. As per GervanoRA findings, 10 clinical trials – had been withdrawn for Multiple Sclerosis and a total of 38 trials have been terminated due to reasons like safety, efficacy, lack of funding, etc.
Report Coverage:
 Key Pipeline Events
 Drug Pipeline Analysis by Stage of Development, Geography, RoA, MoA, Drug Class, and Drug developments by Companies, Universities and Institutes.
 Disease Overview
 Epidemiology and Epidemiology Forecast
 Deals Activities
 Total Drug Approvals for the Treatment of therapeutics (From 2010)
 Estimated Drug Approval Timelines for all Pipeline Drugs
 Patent Analysis of Approved Drugs
 Clinical Trials Summary
 Terminated and Discontinued Drugs Projects
 Current and Future Competitive Landscape of Companies
 Key Companies with Drug Profiles and Drug Milestones
 Key Companies SWOT Analysis
 Emerging Companies with Profiles
 Universities and Institutes with Drugs in Pipeline

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.
At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.
For more details, please visit our website: www.gervanora.com
Connect with us on LinkedIn @ https://in.linkedin.com/company/gervanora-data-services-llp

GervanoRA Data Services LLP
Goa IT Innovation Center
Goa Chamber of Commerce and Industry Bldg.
South Goa, Goa
INDIA
403722.

India (Head Office)
Mr. Ramu Jadhav
GervanoRA Data
Services LLP
Verna, Goa - 403722
India
sales@gervanora.com
Ph. No. +91(0)832-2783283

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GervanoRA Added Multiple Sclerosis: Pipeline Analysis- 2018to its Report Store here

News-ID: 1151142 • Views: 223

More Releases from GervanoRA Data Services

GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Hemophilia A - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report. GervanoRA’s pipeline analysis and opportunity assessment report “Hemophilia A: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Hemophilia A pipeline molecules for the opportunities in the
GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Schizophrenia - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report. GervanoRA’s pipeline analysis and opportunity assessment report “Schizophrenia: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Schizophrenia pipeline molecules for the opportunities in the competitive space by
GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Beta-Thalassemia Pipeline Drugs - Pipeline Analysis, Opportunity Assessments, Epidemiology Forecast, Market Dynamics, H2 2019 . GervanoRA’s pipeline analysis and opportunity assessment report “Beta-Thalassemia: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Beta-Thalassemia pipeline molecules for the opportunities in the
GervanoRA Announced the Release of Opportunity Assessment Report Titled “Aggre …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Aggressive Large B-cell Lymphoma Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018. GervanoRA’s pipeline analysis and opportunity assessment report “Aggressive Large B-cell Lymphoma: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Aggressive Large

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning